Replies to post #225827 on Biotech Values

[DewDiligence]

ENTA reports phase-2a NASH data for EDP-305—primary/secondary endpoints met in high-dose arm:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151356515

The rate of pruritis— 51% in the high-dose arm (with a 21% discontinuation rate due to this AE)—could be a concern.

CC at 4:30pm ET.